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First discovered and studied as a major activator 
of immune and inflammatory function via its ability
to induce expression of genes encoding cytokines,
cytokine receptors, and cell-adhesion molecules [1,2],
the transcription factor nuclear factor (NF)-κB
recently has been linked to control of cell growth 
and oncogenesis. The roles for NF-κB in cancer appear
to be complex, but are likely to involve the ability of this
transcription factor to control apoptosis and cell-cycle
progression, and possibly cell differentiation,
angiogenesis and cell migration. Importantly, it has
been reported that NF-κB is activated in cancer cells
by several chemotherapies and by radiation, and that
in many cases this response inhibits the ability of the
cancer therapy to induce cell death [3]. Here, we
discuss the potential for the development of inhibitors
of NF-κB as primary as well as adjuvant approaches
to cancer therapy.
The NF-κB family and its regulation
The five members of the NF-κB family are p50/p105
(NF-κB1), p52/p100 (NF-κB2), c-Rel, RelB, and p65
(RelA). These proteins are characterized by their
Rel homology domains, which control DNA binding,
dimerization and interactions with inhibitory factors
known as IκB proteins (reviewed in Refs [1,2]). Three
major forms of IκB have been identified, IκBα, IκBβ,
and IκBε, which have been generally shown to localize
NF-κB proteins in the cytoplasm [1,2]. An unusual
member of the IκB family is Bcl-3, which interacts
with p50 and p52 subunits of NF-κB to regulate 
their activity. For example, association of Bcl-3 with
the p52 subunit strongly enhances the potential of 
p52 to activate transcription of an NF-κB-dependent
reporter [1,2]. In most cell types, NF-κB complexes are
predominantly cytoplasmic and thus transcriptionally
inactive until a cell is activated by a relevant stimulus.
In response to pro-inflammatory cytokines such as
tumour necrosis factor (TNF) and interleukin (IL)-1,
bacterial lipopolysaccharide (LPS), or a variety of
other stimuli, IκBα and IκBβ are phosphorylated on
two serine residues located within the N-terminal
portion of the peptides [1,2,4]. This phosphorylation
of IκB results in ubiquitination and subsequent
degradation by the 26S proteasome. A high-molecular-
weight complex (IκB kinase, or IKK) responsible for
phosphorylating IκBα and IκBβ was recently
identified, which contains two key catalytic subunits,
IKKα and IKKβ [reviewed in Ref. 4]. Degradation of
the IκB proteins results in the liberation of NF-κB
allowing translocation to the nucleus, where it can
regulate the expression of specific genes typically
involved in immune and inflammatory responses 
and in cell growth control [1,2].
NF-κB and oncogenesis
v-Rel, a viral homologue of c-Rel, was identified as
the transforming gene of an avian retrovirus which is
highly oncogenic and causes aggressive tumors in
chickens (reviewed in Refs [3,5]). More relevant to
human cancer, the genes encoding c-Rel, NF-κB2
(p100/p52), and Bcl-3 are amplified and/or rearranged
in certain cancers. For example, the Bcl-3 gene was
localized to a [t(14,19) (q32;q13.1)] chromosomal
translocation found in some B-cell chronic lymphocytic
leukemias and is overexpressed in certain B-cell
neoplasms [3,5]. Mutations in the gene encoding
IκBα have been detected in Hodgkin’s lymphoma [6]
and are suggested to contribute to the constitutively
active NF-κB in Hodgkin’s cells. This implies a tumor
suppressor function for IκB as well as an involvement
of NF-κB in this disease (see below).
Other evidence links NF-κB with oncogenic
transformation. For example, the Tax oncoprotein from
the human T-cell leukemia virus-I (HTLV-I) induces
NF-κB activity, and activation of NF-κB was shown to
be required for transformation of rat fibroblasts by 
the HTLV-I Tax protein [3]. Similarly, most viral
transforming proteins stimulate NF-κB transcriptional
activity at one level or another [7]. Consistent with a
possible role in transformation and tumorigenesis,
many human-derived, solid-tumor cell lines display
increased nuclear NF-κB (p50–p65 heterodimer)
levels and activity [3], although this does not always
reflect the natural state of the tumor.
More evidence supports the involvement of 
NF-κB in oncogenesis. First, it was shown that
inhibition of NF-κB by expression of a modified form 
of IκBα (super-repressor IκBα) blocked focus
formation induced by oncogenic H-Ras in NIH3T3 
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cells (reviewed in Ref. [3]). Consistent with this
finding, Ras-induced transformation is blocked by
dominant-negative forms of IKK which block NF-κB [8].
Second, it was shown that the oncogenic fusion protein
BCR–ABL associated with chronic myelogenous
leukemia and some cases of acute lymphoblastic
leukemia activated NF-κB, and that tumorigenesis
driven by BCR–ABL-expressing cells could be blocked
by expression of the super-repressor IκBα [3].
Additionally, NF-κB was shown to be activated in
Hodgkin’s lymphoma, and inhibition of NF-κB blocked
growth of these cells [9]. As mentioned earlier, there
are numerous reports of NF-κB being activated in a
variety of tumor cell lines grown in vitro [3]. For
example, the classic form of NF-κB (p50–p65) has been
shown to be activated (i.e. it has nuclear localization)
in breast cancer cell lines and in some breast tumors
[10]. Our observations suggest that NF-κB appears to
be dysregulated in breast cancer, but we have found
that human breast tumors more typically display an
accumulation of nuclear p52 and Bcl-3 along with
c-Rel rather than p65 [11]. Recently, it has been
shown that inhibition of NF-κB in head and neck
squamous cell carcinoma inhibits cell survival and
tumor growth [12]. Consistent with the observations
described above, NF-κB is activated by most, if not all,
oncoproteins through signal transduction cascades
that ultimately promote NF-κB nuclear translocation
or stimulate inherent transcriptional activity [3].
It should be noted that much of the evidence
linking NF-κB with oncogenesis has been obtained
using the so-called super-repressor form of IκBα to
block NF-κB. Thus, experiments have utilized cell
lines that stably express the modified, degradation-
resistant IκBα or have utilized adenoviral delivery of
the inhibitor [3]. Obviously, if IκB can inhibit 
NF-κB-independent pathways, then the proposed
link between NF-κB and oncogenesis can be called
into question. This caveat holds for any inhibitor that
is not specific for NF-κB.
Apparent roles for NF-κB in oncogenesis involve
suppression of apoptosis, induction of proliferation,
cell invasion and angiogenesis
Numerous studies have indicated that NF-κB
activation can block cell-death pathways (reviewed in
Ref. [3]). Thus, it was shown that NF-κB activation is
required to protect cells from the apoptotic cascade
induced by TNF and other stimuli. NF-κB activates
TRAF1 and -2 and c-IAP1 and -2 to block potential
TNF-induced caspase-8 activity. Other anti-apoptotic
genes have been shown to be activated by NF-κB and
include the Bcl-2 homologs A1/Bfl-1, Bcl-xL, IEX-1,
and XIAP. Of significant interest regarding the
suppression of apoptosis are the observations that
NF-κB can antagonize p53 function, possibly through
the cross-competition for transcriptional co-activators
[13]. However, other research groups have found a
dependence on NF-κB for p53-dependent apoptosis
[14]. The potential of NF-κB to function as a
pro-apoptotic factor is discussed below.
It has been proposed that suppression of apoptosis
is associated with oncogenic potential. Inhibition of
NF-κB, via expression of the super-repressor IκBα,
leads to the induction of apoptosis when an oncogenic
allele of H-Ras (RasV12) is expressed (reviewed in
Ref. [3]), suggesting that one role for NF-κB activation
is to suppress transformation-associated apoptosis.
Other evidence suggests that inhibition of NF-κB in
transformed cells can induce apoptosis. Additionally,
activation of NF-κB by growth factors suppresses the
apoptotic response induced by c-Myc expression
during growth factor deprivation.
A further mechanism whereby NF-κB might be
involved in oncogenesis is through the promotion of
cell proliferation. NF-κB and Bcl-3 can promote 
cell growth through binding to the promoter of 
cyclin D1 and thus stimulating gene transcription 
(reviewed in Ref. [3]). Upregulation of cyclin D1 gene
expression by NF-κB is associated with enhanced
transition from G
1 
to S phase and retinoblastoma (Rb)
hyperphosphorylation (Fig.1).
What other NF-κB-regulated genes or processes
might contribute to oncogenesis? Cox-2, a protein
involved in inflammation, is found upregulated in
more aggressive forms of colorectal cancer, is known
to be transcriptionally activated by NF-κB [1,2] and is
known to promote angiogenesis [15]. Inhibition of
NF-κB suppressed angiogenesis along with vascular
endothelial growth factor (VEGF) and IL-8 expression
in one model [16], but it is unclear whether this is 
an indirect response as smaller tumors caused by
inhibition of NF-κB could be less hypoxic and therefore
have less angiogenesis. Relative to other aspects of
oncogenic control, NF-κB is known to regulate
expression of cell-adhesion molecules [1,2] and
cell-surface proteases (such as MMP-9 and MMP-2,
see Ref. [3]). These observations are consistent with
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Fig. 1. Model for the
activation of nuclear
factor (NF)-κB by a variety
of inducers and for the
nuclear response
controlled by NF-κB.
Inducers of NF-κB activate
IκB kinase (IKK), which
leads to phosphorylation of
IκB subunits on N-terminal
serines. Phosphorylated




of NF-κB in the nucleus. In
the nucleus, NF-κB binds
to regulatory regions in
promoters and enhancers
to stimulate transcription
of genes associated with
oncogenesis, suppression
of apoptosis, and invasion.
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reports indicating that NF-κB can promote metastasis
[17,18]. Recently, it was shown that TNF-null 
animals are inhibited in their ability to undergo skin
carcinogenesis [19]. As NF-κB positively regulates 
TNF gene expression and as TNF activates NF-κB [1,2],
these results might correlate with a role for NF-κB in
skin carcinogenesis. Consistent with the involvement
of cytokines in cancer, it has been suggested that the
upregulation of NF-κB in head and neck squamous
cell carcinoma promotes pro-inflammatory cytokine
production and possibly metastasis [20]. Similarly,
TNFα plays an important role in multiple myeloma
through the NF-κB-dependent upregulation of IL-6 in
bone marrow stromal cells [21]. IL-6 promotes growth
and survival of multiple myeloma cells. More recently,
NF-κB has been shown to block differentiation of
myoblasts into myofibers through the induced
post-transcriptional loss of MyoD mRNA. [22]. 
Thus, it is possible that NF-κB activation could
promote loss of differentiation in certain tumors.
Current approaches to inhibit NF-κB: concern
about specificity?
Original approaches to inhibit NF-κB included
expression of the super-repressor form of IκBα and the
SN50 peptide, which blocks the nuclear localization of
the p50 NF-κB subunit [3,23]. Recently, proteasome
inhibitors have been used to block NF-κB nuclear
localization through inhibition of IκBα degradation
and the processing of the p105 NF-κB precursor
[2,23,24]. Several studies have shown that proteasome
inhibitors have significant anti-tumor activity in
murine xenograft models [24–26], and one of these,
PS-341, inhibits NF-κB and, correspondingly, inhibits
cell survival, tumor growth and angiogenesis in
squamous cell carcinoma tumor models [27]. As the
major proteolytic system in eukaryotic cells [28],
however, the ubiquitin–proteasome pathway controls
the breakdown of most cellular proteins, and thereby
influences a variety of physiological processes.
Obviously, a proteasome inhibitor will affect the
stability of numerous proteins normally controlled by
the ubiquitin–proteasome degradation pathway.
Specificity therefore, regarding NF-κB as a unique
target, is an issue with these types of agents.
Other molecules have been shown to inhibit 
NF-κB, including a peptide that blocks the
interactions of IKKγwith the catalytic core of IKK,
the non-steroidal anti-inflammatory drug (NSAID)
sulindac, cyclopentenone prostaglandins, arsenic
trioxide, thalidomide, a variety of anti-oxidants,
natural products such as parthenolide and
resveratrol, and pharmaceutically developed
synthetic small-molecule inhibitors of the IKK
complex [23,29,30]. With relevance to cancer,
resveratrol was shown to induce apoptosis of
Ras-transformed cells, and sulindac also induced 
cell death in certain transformed cells [3,23]. Arsenic
trioxide, which directly modifies IKK on a critical
cysteine, has shown efficacy in several hematological
malignancies [29,31]. Recently, a drug (PS-1145) was
identified that blocks IκB kinase (IKK) and has
potent NF-κB inhibitory properties [32]. PS-1145
blocks multiple myeloma cell proliferation but not as
effectively as the proteasome inhibitor PS-341 [32].
Overall, these data underscore the potential
relevance of targeting NF-κB in cancer through
monotherapies that block different constituents in
the NF-κB signal-transduction pathway.
NF-κB and chemo- and radio-resistance: is NF-κB
always anti-apoptotic?
The realization that NF-κB can inhibit apoptosis led
us to examine whether or not NF-κB is induced by
chemotherapy and whether it plays a role in blocking
the efficacy of cancer chemotherapies and radiation.
We showed that HT1080 fibrosarcoma cells exposed to
ionizing radiation or to the chemotherapy daunorubicin
exhibited enhanced activation of NF-κB [3].
Inhibition of NF-κB under these experimental
conditions led to a dramatically improved apoptotic
response to ionizing radiation or daunorubicin
treatment as compared with the control cells. HT1080
fibrosarcoma tumors grown in nude mice were
induced to undergo apoptosis when infected with an
adenovirus expressing a modified form of IκBα along
with systemic delivery of the chemotherapeutic agent
CPT-11 [3]. Other tumors (e.g. those derived from the
colorectal tumor cell line LOVO) showed basically
identical responses to the combined treatment. In
fact, LOVO tumors could be eliminated with CPT-11
systemic treatment and with adenoviral delivery of
IκBα [3]. The use of the proteasome inhibitor PS-341
as a systemic inhibitor of NF-κB in conjunction with
CPT-11 treatment also led to significantly improved
chemotherapeutic responses through enhanced
apoptosis [33]. Lactacystin, a structurally unrelated
proteasome inhibitor, has also been reported to
enhance apoptosis induced by drugs such as etoposide
and doxorubicin [3]. It should be noted that wild-type
p53 is apparently not needed for the enhanced
apoptotic response observed with chemotherapy plus
NF-κB inhibition, given that the response occurs in
cancer cells that have mutated or deleted p53 [33].
Similar to the chemotherapy data, inhibition of
NF-κB sensitized LOVO cells to radiation with an
approximately 80% reduction in tumor volume using
xenografts receiving radiation and PS-341 [34].
The form of chemotherapy used might determine
whether NF-κB has a pro- or anti-apoptotic effect [3].
For example, the majority of chemotherapies that we
have studied induce some form of DNA damage, and
inhibition of NF-κB activation promotes cell death.
However, it was proposed recently that NF-κB might
be required for Taxol-induced cell death [35]. This is
consistent with studies that suggest that NF-κB 
can function pro-apoptotically based on the type of
stimulus to which cells are exposed. For example, 
cell death induced by hydrogen peroxide has been
reported to require NF-κB, and there is a report that
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NF-κB is required for p53-dependent cell death [14].
More studies are needed to determine chemotherapy
specificity and potential tumor specificity of NF-κB in
controlling cancer therapy efficacy.
Current clinical trial data relevant to the inhibition
of NF-κB
Several agents that are able to inhibit NF-κB 
function are currently in clinical use as cancer
chemotherapeutics, whereas others are undergoing
clinical development. One of the drugs in the former
category is arsenic trioxide (ATO), whose use as
Fowler’s solution for the treatment of chronic
myelogenous leukemia was first advocated in the
19th century. More recently, ATO was reported to
have activity against promyelocytic leukemia in
studies from China [31]. A multicenter trial in the 
US in patients with relapsed acute promyelocytic
leukemia (APL) found a complete response rate of
85% [36], and ATO has been approved by the Food 
and Drug Administration for that indication. 
Studies have also found that ATO has comparable
activity in patients with newly diagnosed APL [37].
ATO is being evaluated in ongoing clinical trials in
patients with other hematological and solid tumors.
Indeed, preliminary evidence of some activity in
patients with multiple myeloma has recently 
been reported [36].
Thalidomide is another agent in clinical use that
inhibits NF-κB, which it does at least partly by
inhibiting IκB kinase activity [30]. In patients with
refractory multiple myeloma this drug has substantial
activity, with a response rate of up to 32% [38]. Recent
studies using combinations with other agents such 
as dexamethasone suggest that such regimens can
have even greater efficacy (for example, see Ref. [39]).
Interestingly, dexamethasone can inhibit NF-κB
through mechanisms distinct from that of
thalidomide [23]. These encouraging findings have
prompted trials in other hematologic malignancies
that have documented some activity in Hodgkin’s and
non-Hodgkin’s lymphomas [40]. By contrast, while
there is a response rate in AIDS-related Kaposi’s
sarcoma [41], the results with single agent thalidomide
in other solid tumors have been more disappointing.
Occasional responses have been noted in patients with
gliomas [42] and androgen-independent prostate
cancer [43], but of those patients who have derived
any benefit most have exhibited stable disease rather
than regression. As is the case in myeloma there is the
possibility that combinations of thalidomide with
standard chemotherapeutic agents may prove more
efficacious, and such studies are currently underway
(for example [44]).
While ATO and thalidomide were already in
clinical use before their abilities to inhibit NF-κB were
identified, several newer classes of chemotherapeutics
are in development that were intended, at least in
part, to target NF-κB. The best example of agents in
this category are proteasome inhibitors, and
specifically PS-341 [24]. Several Phase I studies of
this drug have been completed, and excitement has
been generated in the field of multiple myeloma
research as significant activity was seen in that patient
population including one complete response [45].
This prompted Phase II trials, which are currently
underway [46]. In patients with solid tumors, the
drug has been well-tolerated and an occasional
response has been seen (for examples, see Refs [47,48]).
Based on some of the preclinical data described
earlier, combination Phase I trials of PS-341 with
standard chemotherapy drugs such as CPT-11 and
gemcitabine are ongoing, and if successful will lead 
to Phase II studies where their promise can be better
evaluated. Given that proteasome inhibition also
augments radiation sensitivity, clinical trials
evaluating this approach are also underway.
With respect to the available clinical data, it is
interesting to note that drugs that target NF-κB such
as thalidomide and PS-341 have to date shown the
greatest success as single agents in the therapy of
hematological malignancies. This is perhaps
reflective of the important role of NF-κB in the 
biology of diseases such as multiple myeloma where
adherence of these cells to bone marrow stroma
triggers synthesis of the myeloma survival and
growth factor IL-6 through an NF-κB-dependent
mechanism [49]. The role of NF-κB in anti-apoptotic
signaling has also raised new hopes that inhibitors will
enhance the efficacy of conventional chemotherapeutic
drugs. Because the NF-κB inhibitors in current
clinical use might also work through other
mechanisms (such as interruption of growth signaling
pathways [50]), it will be difficult to determine how
much of their activity is a result of their impact on
NF-κB. The application of future agents such as
IKK inhibitors that target the NF-κB signaling
cascade more specifically will be more helpful in this
regard. From a clinical perspective, a Phase III trial
randomizing patients to, for example, either CPT-11
or CPT-11 and a specific NF-κB inhibitor would be
required to prove that the preclinical xenograft data
can be reproduced in a human population. Although
such testing is likely to be several years away, at this
time it appears to be one of the promising approaches
to improving the clinical care and outcome of cancer
patients worldwide.
Concluding remarks
There is significant enthusiasm from cell culture
experiments and animal models for the use of NF-κB
inhibitors as a new anti-cancer therapy. However, it is
presently unclear whether this type of approach will be
of general applicability. Concerns range from the fact
that current NF-κB inhibitors are not specific to issues
regarding the potential pro-apoptotic and critical
immunological functions of NF-κB. Furthermore,
another concern is the lack of knowledge about the
specific roles of different NF-κB subunits, some of
which might not be inhibited by drugs that block
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IKK activity or proteasome function. Moreover, the
role of NF-κB could be different in different tumor
types: for example, the function that NF-κB plays in
leukemia and lymphoma might be different from that
in solid tumor cells. Nevertheless, the current data are
promising enough to strongly consider careful studies
to dissect the roles of NF-κB in a variety of cancers and
to determine the applicability of inhibiting NF-κB as
an adjuvant approach in standard approaches to
cancer therapy.
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